Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid

Stock News

09/24

YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.

On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.

As China's AI medical transformation driver, YIDU TECH has built a "data-algorithm-scenario" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of "medical-pharmaceutical-insurance-patient".

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1120477928"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120477928\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120477928?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 11:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120477928","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid","media":"Stock News","content":"<p>YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.</p>\n<p>On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.</p>\n<p>As China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-24 11:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.</p>\n<p>On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.</p>\n<p>As China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07226","symbol_name":"南方两倍做多恒科","start_time":0,"source_url":"","article_id":"1120477928","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120477928","pubTimestamp":1758685339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million. On the news front, YIDU TECH announced that its affiliated company Tianjin...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07226":"南方两倍做多恒科","HSCEI":"国企指数","BK1189":"医疗保健技术","BK1617":"AI医疗","BK4134":"信息科技咨询与其它服务","02158":"医渡科技","YANG":"三倍做空富时中国ETF-Direxion","BK4614":"Manus概念股","BK1518":"SaaS概念","III":"信息服务"},"translate_title":"港股快讯|医渡科技(02158)大涨超5%中标SMR001滴眼液III期临床研究项目","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02158":1,"07226":1,"HSCEI":1,"III":1,"YANG":1},"content_text":"YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.\nOn the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.\nAs China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}